ProCE Banner Activity

CE / CME

Cases in CLL: Patient Progressing on BR With Subsequent Ibrutinib Intolerance

Multimedia
In this installment of CCO’s concise patient case series, Jeff P. Sharman, MD, discusses treatment considerations for a patient with CLL who initially progressed on chemoimmunotherapy and was intolerant to subsequent ibrutinib.

Pharmacists : 0.25 contact {hour} ({0.025} CEUs)

Physicians : maximum of 0.25 AMA PRA Category 1 {Credit}

Registered Nurses: 0.25 Nursing contact {hour}

Released: October 01, 2020

Expiration: September 30, 2021

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with chronic lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Choose optimal treatment for relapsed/refractory chronic lymphocytic leukemia based on the available clinical data and expert recommendations
  • Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life
  • Evaluate promising investigational agents and novel combination regimens in chronic lymphocytic leukemia, including efficacy, unique toxicities, and other practical management considerations
  • Manage adverse events associated with treatment approaches for chronic lymphocytic leukemia to ensure treatment compliance as well as improved clinical outcomes and quality of life

Program Director Disclosure

Program Director

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeffrey P Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, Astra Zeneca, Beigene, Genetech, Jannsen, Pharmacyclics, Pfizer, and TG Therapeutics

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeffrey P Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, Astra Zeneca, Beigene, Genetech, Jannsen, Pharmacyclics, Pfizer, and TG Therapeutics

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.25 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.25 contact hours (0.025 CEU). Universal program number is as follows: 0230-9999-20-029-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 01, 2020, through September 30, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with chronic lymphocytic leukemia.